Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel.

Trapé, Adriana Priscila; Liu, Shuying; Cortes, Andrea Carolina; Ueno, Naoto T; Gonzalez-Angulo, Ana Maria

Trapé, Adriana Priscila; Liu, Shuying; Cortes, Andrea Carolina; Ueno, Naoto T; Gonzalez-Angulo, Ana Maria.

Afiliación

Trapé AP; 1. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;
Liu S; 1. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;
Cortes AC; 2. Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.
Ueno NT; 1. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;
Gonzalez-Angulo AM; 1. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX;

J Cancer ; 7(8): 947-56, 2016.

Article en En | MEDLINE | ID: mdl-27313785

Palabras clave

HR-positive/HER2-negative; breast cancer.; paclitaxel; palbociclib; resistance

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Cancer Año: 2016 Tipo del documento: Article